2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropyl methanesulfonate | 949196-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropyl methanesulfonate
• 英文别名: 2-{[1-(Cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropyl Methanesulfonate；[2-[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)benzimidazol-5-yl]sulfonyl-2-methylpropyl] methanesulfonate
• CAS: 949196-64-9
• 化学式: C₂₁H₃₂N₂O₅S₂
• 分子量: 456.627
• InChiKey: KTVPUIDOCWTVOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  112
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropyl methanesulfonate 在 palladium 10% on activated carbon sodium azide 、 氢气 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 42.0h， 生成 2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropan-1-amine
  参考文献：
  名称：

  WO2007/102059

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropanoate 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-{[1-(cyclopropylmethyl)-2-(2,2-dimethylpropyl)-1H-benzimidazol-5-yl]sulfonyl}-2-methylpropyl methanesulfonate
  参考文献：
  名称：

  WO2007/102059

  摘要：

  公开号：

文献信息

• SULFONYL BENZIMIDAZOLE DERIVATIVES
  申请人：Kato Tomoki

  公开号：US20090137584A1

  公开（公告）日：2009-05-28

  This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis.

  本发明涉及化合物公式(I)或其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、m和n分别如本文所述，以及含有这种化合物的组合物，以及这种化合物在治疗CB2受体活性介导的疾病中的应用，例如但不限于炎症性疼痛、伤害性疼痛、神经病理性疼痛、纤维肌痛、慢性腰痛、内脏疼痛、急性脑缺血、疼痛、慢性疼痛、急性疼痛、带状疱疹后神经痛、神经病、神经痛、糖尿病神经病、艾滋病相关神经病、神经损伤、类风湿性关节炎疼痛、骨关节炎疼痛、背痛、癌痛、牙痛、纤维肌痛、神经炎、坐骨神经痛、炎症、神经退行性疾病、咳嗽、支气管收缩、肠易激综合症(IBS)、炎症性肠病(IBD)、结肠炎、脑血管缺血、呕吐，例如癌症化疗引起的呕吐、类风湿性关节炎、哮喘、克罗恩病、溃疡性结肠炎、哮喘、皮炎、季节性过敏性鼻炎、GERD、便秘、腹泻、功能性胃肠疾病、肌肤T细胞淋巴瘤、多发性硬化症、骨关节炎、银屑病、系统性红斑狼疮、糖尿病、青光眼、骨质疏松症、肾小球肾炎、肾脏缺血、肾炎、肝炎、脑卒中、血管炎、心肌梗死、脑缺血、可逆性气道阻塞、成人呼吸系统疾病综合症、COPD、隐源性纤维化性肺泡炎和支气管炎等。
• Sulfonyl benzimidazole derivatives
  申请人：Pfizer Inc

  公开号：US07700618B2

  公开（公告）日：2010-04-20

  This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis.

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其中A，R1，R2，R3，R4，R5，m和n分别如本文所述，并且包含这种化合物的组合物，以及在治疗由CB2受体活性介导的疾病中使用这种化合物，例如但不限于炎症性疼痛，伤害性疼痛，神经病性疼痛，纤维肌痛，慢性腰痛，内脏疼痛，急性脑缺血，疼痛，慢性疼痛，急性疼痛，带状疱疹后神经痛，神经病，神经痛，糖尿病性神经病，艾滋病相关神经病，神经损伤，类风湿性关节痛，骨关节炎疼痛，背痛，癌痛，牙痛，纤维肌痛，神经炎，坐骨神经痛，炎症，神经退行性疾病，咳嗽，支气管收缩，肠易激综合症（IBS），炎症性肠病（IBD），结肠炎，脑血管缺血，恶心，如癌症化疗引起的恶心，类风湿性关节炎，哮喘，克罗恩病，溃疡性结肠炎，哮喘，皮炎，季节性过敏性鼻炎，GERD，便秘，腹泻，功能性胃肠疾病，肠易激综合症，皮肤T细胞淋巴瘤，多发性硬化症，骨关节炎，牛皮癣，系统性红斑狼疮，糖尿病，青光眼，骨质疏松症，肾小球肾炎，肾缺血，肾炎，肝炎，脑卒中，血管炎，心肌梗塞，脑缺血，可逆性气道阻塞，成人呼吸道疾病综合征，COPD，隐源性纤维化性肺泡炎和支气管炎。
• US7700618B2
  申请人：——

  公开号：US7700618B2

  公开（公告）日：2010-04-20
• [EN] SULFONYL BENZIMIDAZOLE DERIVATIVES<br/>[FR] DERIVES DE SULFONYL BENZIMIDAZOLE
  申请人：PFIZER JAPAN INC

  公开号：WO2007102059A1

  公开（公告）日：2007-09-13

  [EN] This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R¹, R² ,R³, R⁴, R⁵, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis.
  [FR] La présente invention concerne des composés de formule (I) : dans laquelle A, R¹, R², R³, R⁴, R⁵, m et n sont tels que définis dans le présent document. L'invention concerne également sur les compositions contenant ces composés et l'utilisation de ces composés dans le traitement d'une pathologie induite par l'activité du récepteur CB2, telle que, mais pas exclusivement, la douleur inflammatoire, la douleur nociceptive, la douleur neuropathique, la fibromyalgie, la lombalgie chronique, la douleur viscérale, l'ischémie cérébrale aiguë, la douleur chronique, la douleur aiguë, la névralgie post-herpétique, les neuropathies, la névralgie, la neuropathie diabétique, la neuropathie liée au VIH, les lésions nerveuses, la douleur liée à la polyarthrite rhumatoïde, la douleur ostéoarthritique, la dorsalgie, la douleur cancéreuse, la douleur dentaire, la fibromyalgie, la néphrite, la sciatique, l'inflammation, la maladie neurodégénérative, la toux, la bronchoconstriction, le syndrome du côlon irritable, la maladie intestinale inflammatoire, la colite, l'ischémie cérébrovasculaire, le vomissement, tel que le vomissement induit par une chimiothérapie, la polyarthrite rhumatoïde, l'asthme, la maladie de Crohn, la colite ulcérative, l'asthme, la dermatite, la rhinite allergique saisonnière, le reflux gastro-oesophagien (GERD), la constipation, la diarrhée, les troubles gastro-intestinaux fonctionnels, le syndrome du côlon irritable, le lymphome cutané des lymphocytes T, la sclérose en plaques, l'ostéoarthrite, le psoriasis, le lupus érythémateux systémique, le diabète, le glaucome, l'ostéoporose, la glomérulonéphrite, l'ischémie rénale, la néphrite, l'hépatite, l'accident vasculaire cérébral, la vascularite, l'infarctus du myocarde, l'ischémie cérébrale, l'obstruction des voies respiratoires réversible, le syndrome de la détresse respiratoire de l'adulte, la BPCO, l'alvéolite fibrosante cryptogénétique et la bronchite.
• WO2007/102059
  申请人：——

  公开号：——

  公开（公告）日：——